Massachusetts General Hospital Researchers Develop CogniShield Advanced Supplement

Massachusetts General Hospital (MGH) researchers have developed a new cognitive support supplement featuring five ingredients called CogniShield Advanced.

The formulation was developed after years of in vitro research on a newly developed model of the aging brain known as a 3D neural cell culture model, which allows for the rapid testing of drugs and natural products in a human brain-like environment.

Since 2014, the researchers have tested more than 1,700 FDA-approved drugs and 4,000 natural products. CogniShield is one of over 50 synergistic combinations that are being slated for investigation. A human clinical trial for CogniShield Advanced will begin in 2027.

Kevin Rynearson, head of research, and George Alex, co-founder and CEO of CogniShield Global, spoke with Nutraceuticals World about what went into the development of this supplement.

Subscribe to our newsletter to stay up to date with all our content.

A New Model for High-Throughput Testing

The model used in the development of CogniShield Advanced, invented by MGH researchers, is the first three-dimensional neuron culture model that recapitulates interactions with an assembly of neurons, astrocytes, and microglia “in a matrix that enables screening of molecules that demonstrate impacts on plaques, tangles, and microglial activation of neuroinflammation,” said Rynearson.

Traditional models screen one compound at a time using animal models, which is expensive and time-consuming to the point where screening thousands of compounds is a technical impossibility. By contrast, “to date, the neuroscience team at MGH has screened 4,000 natural compounds over more than a decade.”

“The model allows us to observe amyloid accumulation, neuroinflammation, and neuronal changes in a controlled system. When you’re young, you clear amyloid beta as part of your healthy innate immune system, but with age, this capability slows and neuroinflammation can take hold,” said Rynearson.

“The MGH aging brain model recapitulates brain function that’s in disrepair,” he continued. “It’s a challenge model: an adverse environment. After screening over 4,000 natural products, the neuroscientists at MGH using the MGH Aging Brain Model found 50 combinations of compounds that restored some elements of the normal healthy function.”

The original CogniShield formulation came out of this model. While it doesn’t capture the intricacies of an actual human brain, it’s an efficient and insightful discovery and screening tool, he noted, providing much-needed biological insight.

“One of the biggest advantages of the MGH model is its adaptability. It’s only limited by your creativity … The system allows us to observe changes in a broader, more phenotypic way.”

Compared to any other model, it allows neuroscientists to pivot quickly across different hypotheses.

The Formula

The team used the model to screen natural compounds with molecular structures expected to cross the blood-brain barrier against two drivers of brain aging: microglial uptake and clearance of beta-amyloid, and neuroinflammation measured by TNF-α. The formulation base consists of ipriflavone, quercetin extracted from Sophora japonica bud, and fisetin from Rhus succedanea stem, with fenugreek seed powder used to enhance bioavailability of quercetin and fisetin.

“What distinguished these three was not novelty — each is a well-characterized compound already in use — but performance in combination … Two mechanistically distinct synergies were observed, one on amyloid clearance and one on TNF-α reduction, with a shared component affecting both,” Rynearson said.

Cognizin Citicoline was also included in the formulation for separate benefits. “It contributes to neuronal membrane integrity, neurotransmitter synthesis, and brain energy metabolism, and it carries human clinical evidence at the dose used,” said Rynearson.

In contrast to many multi-ingredient formulas, which are assembled one ingredient at a time from published literature and consumer familiarity, “this formulation was derived from functional screening in brain tissue models against defined pathological readouts, selected for combination effects rather than single-agent activity, disclosed at full label with standardized actives and no proprietary blend, and manufactured under cGMP with per-batch potency verification.”

An important caveat: the synergy findings are in vitro and preclinical. Health claims can’t be established until a randomized, double-blind, placebo-controlled trial slated for next year is completed.

The Human Clinical Trial

The upcoming decentralized clinical study will be conducted in older adults who report subjective cognitive concerns, but carry no diagnosis of neurodegenerative disease.

“It is designed to hold itself to pharmaceutical standards rather than supplement-industry norms: pre-specified primary, secondary, and exploratory endpoints; matching placebos indistinguishable from the active products; randomization stratified to balance sex and age; a placebo lead-in period that both establishes adherence before randomization and moves the analytic baseline past the initial exposure to the test battery, blunting the practice effects that have compromised so much of this literature. Dosing runs several months, with participation extending somewhat longer to accommodate screening and lead-in,” said Rynearson.

Cognition will be measured through a battery of validated tests on attention, learning, memory, and executive function, combined into a global composite. Subjective experience, by contrast, is a secondary outcome.

Elevating the Field of Cognitive Nutrition Research

Alex discussed industry-wide efforts that could enhance the credibility of research on nutritional interventions for cognitive longevity.

Key gaps include:

• Soft endpoints, based on subjective results that are sensitive to practice effects, mood, sleep, and education, creating ambiguity instead of answers;
• Wrong time frames in wrong populations: “studies run 12 to 24 months and enroll people already past the window in which a nutrition intervention would matter most. A short study in the wrong age group looks like failure even when the biology is sound”;
• Single-ingredient thinking, inherited from pharmaceutical conventions of testing one molecule at a time, rather than examining synergies in a way that no single-agent trial can;
• Inconsistencies in product dose, form, and overall quality over a multi-year trial or two separate trials;
• Weak controls with open-label or unblinded designs, “where expectation alone can move a cognitive score.”

“The near-term advance is measurement. Blood-based markers of neurodegenerative pathology have moved from research tool to a cleared diagnostic, making it possible to measure the underlying biology directly before symptoms manifest rather than infer it from questionnaires and test scores. Today’s cleared assays, including C2N Diagnostics’ PrecivityAD2, are indicated for people who already have symptoms; the frontier is pushing that objectivity earlier, into midlife, when a nutritional intervention actually matters,” said Alex.

As trials incorporate novel, validated biomarkers, they’ll get shorter, smaller, and cheaper, Alex predicted, by looking more closely at causes rather than downstream effects, all while “generating reliable and reproducible data that an academic journal can trust.”

MGH’s aging-brain model and other 3-D cell-based platforms will take a bigger picture of preclinical work, allowing research teams to become more selective and discover new biomarkers that can be used in a clinical study.

Importantly, these shifts make prevention something that can be measured, Alex noted. “Interventions that maintain brain health are most valuable years before decline is perceptible, and until now there was no way to demonstrate benefit on that timescale … Objective markers let researchers verify in months that something is working in a 55-year-old, the same logic that transformed preventive care elsewhere in medicine once blood screening replaced waiting for symptoms.”